Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients
暂无分享,去创建一个
[1] J. Izopet,et al. Antibody titers and breakthrough infections with Omicron SARS-CoV-2 , 2022, Journal of Infection.
[2] O. Thaunat,et al. Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series , 2022, Annals of Internal Medicine.
[3] J. Izopet,et al. Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients , 2022, American Journal of Transplantation.
[4] J. Fillaux,et al. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays , 2021, Microbiology spectrum.
[5] P. Demers,et al. Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. , 2021, JAMA.
[6] H. Jäck,et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.
[7] J. Izopet,et al. Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant , 2021, JAMA network open.
[8] A. Nongnuch,et al. SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study) , 2021, American Journal of Transplantation.
[9] J. Izopet,et al. Clinical performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2 antibodies directed to the spike protein , 2020, Journal of Clinical Virology.